Antisense Therapy for Infectious Diseases

Simple item page
dc.contributor.authorButhelezi, Lwanda Abonga
dc.contributor.authorPillay, Shandre
dc.contributor.authorNtuli, Noxolo Nokukhanya
dc.contributor.authorGcanga, Lorna
dc.contributor.authorGuler, Reto
dc.date.accessioned2023-09-19T08:35:38Z
dc.date.available2023-09-19T08:35:38Z
dc.date.issued2023-08-21
dc.date.updated2023-08-25T12:37:25Z
dc.description.abstractInfectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.
dc.identifierdoi: 10.3390/cells12162119
dc.identifier.apacitationButhelezi, L. A., Pillay, S., Ntuli, N. N., Gcanga, L., & Guler, R. (2023). Antisense Therapy for Infectious Diseases. <i>Cells</i>, 12(16), 2119. http://hdl.handle.net/11427/38762en_ZA
dc.identifier.chicagocitationButhelezi, Lwanda Abonga, Shandre Pillay, Noxolo Nokukhanya Ntuli, Lorna Gcanga, and Reto Guler "Antisense Therapy for Infectious Diseases." <i>Cells</i> 12, 16. (2023): 2119. http://hdl.handle.net/11427/38762en_ZA
dc.identifier.citationButhelezi, L.A., Pillay, S., Ntuli, N.N., Gcanga, L. & Guler, R. 2023. Antisense Therapy for Infectious Diseases. <i>Cells.</i> 12(16):2119. http://hdl.handle.net/11427/38762en_ZA
dc.identifier.ris TY - Journal Article AU - Buthelezi, Lwanda Abonga AU - Pillay, Shandre AU - Ntuli, Noxolo Nokukhanya AU - Gcanga, Lorna AU - Guler, Reto AB - Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases. DA - 2023-08-21 DB - OpenUCT DP - University of Cape Town IS - 16 J1 - Cells LK - https://open.uct.ac.za PY - 2023 T1 - Antisense Therapy for Infectious Diseases TI - Antisense Therapy for Infectious Diseases UR - http://hdl.handle.net/11427/38762 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/38762
dc.identifier.vancouvercitationButhelezi LA, Pillay S, Ntuli NN, Gcanga L, Guler R. Antisense Therapy for Infectious Diseases. Cells. 2023;12(16):2119. http://hdl.handle.net/11427/38762.en_ZA
dc.publisherMultidisciplinary Digital Publishing Institute
dc.publisher.departmentPathology
dc.publisher.facultyHealth Sciences
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceCells
dc.source.journalissue16
dc.source.journalvolume12
dc.source.pagination2119
dc.source.urihttps://www.mdpi.com/journal/cells
dc.titleAntisense Therapy for Infectious Diseases
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cells-12-02119-v2.pdf
Size:
2.03 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles